Exagen Inc. XGN Capitalization of research and experimentation costs
Capitalization of research and experimentation costs at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept exdx:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCapitalizationOfResearchAndExperimentationCosts.
The official record: Exagen Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s capitalization of research and experimentation costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exagen Inc.'s capitalization of research and experimentation costs?
- Exagen Inc. (XGN) reported capitalization of research and experimentation costs of $1.89M in Q4 2025.
- How has Exagen Inc.'s capitalization of research and experimentation costs changed year-over-year?
- Exagen Inc.'s capitalization of research and experimentation costs decreased by 35.6% year-over-year, from $2.94M to $1.89M.
- What does capitalization of research and experimentation costs mean?
- This metric represents the capitalized costs associated with research and experimentation activities that are deferred for tax purposes. It reflects the tax benefit expected to be realized in future periods as these capitalized expenses are amortized. Monitoring this balance helps investors understand the company's long-term tax planning and the impact of R&D investment cycles on future cash tax obligations.